# CORXEL Pharmaceuticals

> CORXEL Pharmaceuticals is a clinical-stage biopharmaceutical company developing innovative therapies for cardiometabolic diseases worldwide. Spun out of RTW Investments in 2019 (formerly JiXing Pharmaceuticals) and dual-based in Berkeley Heights, New Jersey and Shanghai, CORXEL is advancing a pipeline led by CX11, a differentiated oral small-molecule GLP-1 receptor agonist for obesity and type 2 diabetes, alongside JX10 for acute ischemic stroke and JX09 for hypertension. In January 2026 the company raised up to $287 million in Series D1 financing to push these programs through late-stage clinical trials.

- **Founded:** 2019
- **Headquarters:** Berkeley Heights, New Jersey, United States
- **Founders:** RTW Investments (Founding investor / incubator)
- **Team size:** ~60 employees
- **Products:** CX11, JX10, JX09
- **Notable:** Raised up to $287 million in Series D1 financing in January 2026, one of the year's notable cardiometabolic rounds., Advanced CX11 into Phase 2 in the US and Phase 3 in China., Secured worldwide (ex-China) rights to a differentiated oral GLP-1 asset from Vincentage.

## Products & services

- **CX11** — Investigational oral small-molecule GLP-1 receptor agonist for obesity, overweight and type 2 diabetes, designed for once-daily oral dosing to overcome the limitations of injectable GLP-1 therapies. In Phase 2 in the US and Phase 3 in China.
- **JX10** — A thrombolytic and anti-inflammatory agent in development for acute ischemic stroke.
- **JX09** — A highly selective aldosterone synthase inhibitor in development for hypertension.

## Achievements

- Raised up to $287 million in Series D1 financing in January 2026, one of the year's notable cardiometabolic rounds.
- Advanced CX11 into Phase 2 in the US and Phase 3 in China.
- Secured worldwide (ex-China) rights to a differentiated oral GLP-1 asset from Vincentage.
- Attracted a syndicate of premier healthcare investors including SR One, RA Capital, TCGX and Adage.
- Built a three-program cardiometabolic pipeline spanning obesity, stroke and hypertension with roughly 60 employees.

## Latest updates

- **2026-01** — CORXEL announced completion of a $287 million Series D1 financing to advance CX11 and its broader cardiometabolic pipeline.
- **2024-12** — CORXEL acquired worldwide (excluding Greater China) rights to CX11, an oral small-molecule GLP-1 receptor agonist, from Vincentage.
- **2025-01** — Bolstered leadership with the appointment of CFO Kevin Xie, formerly CFO of Gracell Biotechnologies.

## Links

- Website: https://www.corxelbio.com
- LinkedIn: http://www.linkedin.com/company/corxel-pharmaceuticals

---

Profile page: https://yespress.io/corxel-pharmaceuticals
Published by YesPress — https://yespress.io
Last updated: 2026-07-21